A Study to Evaluate the Antiviral Activity and Safety of HH-003 Injection in Subjects With Chronic Hepatitis B and Hepatitis D Co-infection

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped During the study, the sponsor adjusted the overall clinical development strategy, decided to terminate the enrollment in advance after discussion with the lead investigator.

Conditions

Chronic Hepatitis B and Hepatitis D Co-infection

Interventions

BIOLOGICAL: HH-003 20mg/kg
BIOLOGICAL: HH-003 3mg/kg

Sponsor

Huahui Health